BIIB

Biogen
D

BIIB

250.760
USD
-3.07
(-1.21%)
Post Trading·249.900USD-0.860(-0.34%)
Last updated: · Delayed 15 min
Volume
39,873
EPS
12
Div Yield
-
P/E
44
Market Cap
37,050,792,538
Overview
Related Instruments
ABBV
ABBV
D
ABBVIE
285.67
0.71(0.25%)
286.00+0.33(+0.12%)
AMGN
AMGN
D
Amgen
439.14
-8.24(-1.84%)
440.51+1.37(+0.31%)
GILD
GILD
D
Gilead Sciences
156.070
-1.150(-0.73%)
155.560-0.510(-0.33%)
JNJ
JNJ
D
Johnson & Johnson
263.86
-3.84(-1.43%)
263.09-0.77(-0.29%)
MRK
MRK
D
Merck & Co
145.270
-1.970(-1.34%)
145.280+0.010(+0.01%)
PFE
PFE
D
Pfizer
30.015
-0.400(-1.32%)
30.020+0.005(+0.02%)
REGN
REGN
D
Regeneron Pharmaceuticals
805.40
-14.20(-1.73%)
805.24-0.16(-0.02%)
SNY
SNY
D
Sanofi ADS
41.585
-0.365(-0.87%)
41.390-0.195(-0.47%)
More

Title: Biogen

Sector: Healthcare
Industry: Drug Manufacturers - General
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.